FDA Declares Varian’s New Device Breakthrough Device of the Year 

As per the trusted reports, Varian’s, a company owned by Siemens Healthineers, announced today that they had been given a designation of Breakthrough Device by the U.S. Food and Drug Administration (FDA).

The grant has been given for their latest product for the non-invasive therapy known as cardiac radio ablation (CRA) system, which helps select the patients having refractory ventricular tachycardia (VT).The CRA system developed by the company showed the potential to give a better treatment for patients suffering from refractory VT.

Awareness regarding the benefits of the CRA system, such as less time and better safety, is further increasing its importance among healthcare professionals and institutions.Phillip Cuculich, associated with Washington University School of Medicine, stated that he is really excited about the CRA by Varian’s as a heart rhythm specialist who regularly works with VT patients. It can be considered a breakthrough technology in recent times.

He further added that the invention of the therapy is bringing them closer to offering promising treatment and treatment to the patients suffering from VT and who did not see any benefits from other lines of treatment.The aim of the FDA Breakthrough Device Program is to offer patients with timely access to several medical assistance in the form of treatment and devices. It can offer a better option to manage fatal diseases or conditions that may deteriorate quality of life.